日期: 2024 年 12 月 11 日

Hong Kong – December 11, 2024 – (SeaPRwire) – Recently, BOM Network is proud to unveil its solutions to tokenize a wide range of real-world assets, from real estate to commodities, and use these tokens for trading, lending, or as collateral. Real-World Assets (RWA): The Bridge Between Traditional Finance and Blockchain Revolution In recent years, the crypto market has undergone remarkable growth, but its volatility and limited real-world use cases have often raised concerns. Real-World Assets (RWA) are emerging as a pivotal trend that may fundamentally reshape the blockchain and crypto space by creating a more stable and tangible connection to traditional finance. The tokenization of RWAs allows for real estate, commodities, and other physical assets to be represented on the blockchain, unlocking liquidity and expanding investment opportunities.RWAs bridge the gap between traditional assets and decentralized finance (DeFi), bringing stability, security, and trust into the often volatile crypto markets. This fusion offers several key benefits: Access to Illiquid Assets Increased Liquidity and Market Efficiency Global Access The Future of Banking and RWA Integration BOM Network is one standout project in the RWA space, focusing on integrating blockchain with traditional financial services. BOM Network’s unique approach lies in its emphasis on combining traditional banking services with the efficiency of blockchain, making it an attractive solution for institutions looking to bridge the gap between old and new financial systems. BOM Network has already established partnerships with global financial institutions, offering a scalable and secure way for investors to participate in the RWA market. Its platform is designed for both retail and institutional investors, making it a key player in the future of decentralized finance. By integrating RWAs into its ecosystem, BOM Network aims to drive the mainstream adoption of blockchain technology and create a more efficient, liquid, and globally accessible financial system. As the tokenization of RWAs gains traction, projects like BOM Network are leading the charge toward a more stable, diversified, and globally inclusive crypto market. About BOM Network BOM is the perfect bridge for capital from the real world to the Blockchain world. Meet a huge supply and demand of borrowing and lending from the real world into the cryptocurrency market. RWAs are likely to accelerate institutional adoption of blockchain technology. Moreover, the introduction of RWAs will catalyze regulatory development as governments and financial authorities adapt to this new intersection of traditional assets and blockchain technology. This convergence will bring crypto further into the mainstream, providing a fertile ground for innovation and growth. Social Links X: https://x.com/BOM_Network Telegram: https://t.me/BOMNetworkCommunity YouTube: https://www.youtube.com/@bom_network Media Contact Brand: BOM Network Contact: Media contact Email: support@bomnetwork.io Website: https://bomnetwork.io The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...

SHENZHEN, CHINA, Dec 9, 2024 – (ACN Newswire) – On 6 December, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the first prescriptions for the innovative drug Lumeblue® (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) (the “Product”) have been issued in China, which marks that the first oral methylthioninium chloride enteric-coated sustained-release tablets in China has officially entered clinical application. The Product is indicated for enhancing visualization of colorectal lesions in adult patients undergoing screening or surveillance colonoscopies. Lumeblue® is an oral diagnostic drug that uses patented multi-matrix (MMXTM) technology to deliver active substances directly to the colon and release them locally in a controlled manner. As an enhancer dye, the Product increases the contrast between colorectal lesions and healthy mucosa. The results of the Phase III clinical trial in China show that the Product can significantly improve the detection rate of non-polypoid colorectal lesions (the primary endpoint of the study), leading to an improved detection rate of dangerous lesions such as non-polypoid adenomas (the secondary endpoint)[1]. In addition, the Product can be taken during the bowel preparation step, ensuring that colorectal staining is completed by the time colonoscopy is conducted. This not only enhances the detection rate of colorectal lesions but also potentially simplifies the colonoscopy procedure, making the examination more efficient and improving the screening benefits. According to the diagnosis and treatment data of the Digestive Endoscopy Branch of the Chinese Medical Association, approximately a total of 28 million gastroenteroscopies were completed nationwide in 2012, including 5.83 million colonoscopies. In 2019, approximately 38.73 million gastroenteroscopies were completed nationwide, an increase of 34.62% compared with 2012[2]. The Expert consensus on the early diagnosis and treatment of colorectal cancer in China (2023 edition) recommends colorectal cancer screening for individuals aged 40 to 74[3]. Based on the China Statistical Yearbook (2023), the total population of this age group in China is 643.36 million[4]. With the popularization of early colorectal cancer screening in China, the number of colonoscopies performed is expected to have significant growth potential in the future. Early diagnosis and removal of lesions are crucial for prevention. Lumeblue® provides an innovative solution for colorectal disease screening and management in response to this growing demand. The Product has been approved by the European Medicines Agency (EMA) to be commercialized in the European Union under the trade name Lumeblue® in August 2020. The Group obtained an exclusive license for the Product from Cosmo Technologies Ltd., a fully-owned subsidiary of Cosmo Pharmaceuticals NV, on 3 December 2020. Following its approval in China in June 2024, CMS worked collaboratively across its business segments to ensure the rapid importation of the first batch of products. The Group has also actively leveraged its existing gastroenterology portfolio and resources to orderly advance the commercialization and academic promotion of Lumeblue®, facilitating its successful prescriptions launch in China. With this milestone, CMS’s five innovative drugs have been successfully approved in China and fully entered clinical application. This achievement demonstrates the Group’s ongoing capability of innovation transformation, while reflecting CMS’s commitment to focusing on medical value and fulfilling its corporate social responsibility. Looking ahead, CMS will continue to be patients-centered, efficiently advancing the clinical development and commercialization of innovative products. The Group is dedicated to improving the accessibility and affordability of innovative drugs, benefiting a broader patient population. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group. References: 1. The results of the Product’s Phase III clinical trial in China were published and are available at: https://web.cms.net.cn/en/2022/12/positive-results-for-china-phase-iii-clinical-trial-of-methylthioninium-chloride-enteric-coated-sustained-release-tablets/ 2. Data from the Digestive Endoscopy Branch of the Chinese Medical Association 3. Early Diagnosis and Treatment Group of the Chinese Society of Oncology. “Expert Consensus on Early Diagnosis and Treatment of Colorectal Cancer in China (2023 Edition).” Chinese Medical Journal, 2023, 103(48): 3896-3908. DOI: 10.3760/cma.j.cn112137-20230804-00164 4. National Bureau of Statistics. (2023). China Statistical Yearbook 2023. Retrieved from https://www.stats.gov.cn/sj/ndsj/2023/indexch.htm CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

Nassau, the Bahamas – December 11, 2024 – (SeaPRwire) – FxPro Group, a global leader in financial services and trading, has launched BankPro, a cutting-edge Private Digital Bank designed to redefine digital financial solutions for individuals and corporations. BankPro combines private banking services with advanced investment and trading capabilities, offering clients a seamless, all-in-one application tailored to their financial needs. The launch of BankPro underscores FxPro Group’s commitment to innovation and excellence, leveraging its 25 years of expertise and $120 million in Tier 1 company capital to introduce a next-generation digital banking solution. BankPro is regulated by the Central Bank of The Bahamas and operates with the highest standards of security and compliance. Key Features of BankPro: Multi-Currency Accounts BankPro provides access to over 24 currencies, enabling effortless international transactions at competitive exchange rates. Clients can manage their finances globally with a single account designed for both personal and corporate use. Visa Platinum Cards Clients can access exclusive Visa Platinum cards, offering customizable spending limits, global acceptance, and enhanced security. Additionally, instant virtual cards provide a secure and efficient solution for online transactions, making BankPro a versatile option for all financial activities. Global Banking with Flat Fees BankPro simplifies international banking with flat-fee structures, ensuring transparent and predictable costs. This approach is particularly advantageous for high-value transactions, providing clarity and value for clients engaged in global business and personal finance. Comprehensive Investment and Trading Platform BankPro integrates investment and trading capabilities, allowing clients to manage and grow their portfolios within the same platform. Key features include: Investing in over 2,100 Stocks and ETFs: Clients gain access to major exchanges, including NYSE, Nasdaq, LSE, XETRA, and Euronext. Real-Time Market Data: Active subscriptions include free live pricing from Nasdaq and LSE. Through FxPro Global Markets Ltd., clients can also trade over 200 Derivatives across Forex, Commodities, Metals, Indices, Stocks, and ETFs, enabling portfolio diversification and risk management. Corporate Banking Solutions BankPro offers tailored services for businesses, including multi-currency accounts, streamlined expense management tools, and advanced treasury management solutions. Corporate clients benefit from high-spending Visa Platinum cards, detailed reporting tools, and access to flexible investment options. A Strong Foundation in the Bahamas BankPro operates from its state-of-the-art headquarters in Lyford Cay, Nassau. The facility reflects the company’s commitment to The Bahamas as a central hub for its operations. The company also has an office in the City of London, UK. As a fully regulated entity, BankPro prioritizes security and reliability, holding a professional membership with the Association of International Banks and Trust Companies. The company’s regulatory foundation ensures robust protection for clients, complemented by advanced digital onboarding tools and fraud prevention measures. These features, combined with the FxPro Group’s legacy of excellence, make BankPro a trusted partner for financial services. About FxPro Group With 25 years of experience, the FxPro Group is a global leader in financial services, offering trading solutions across Forex, Commodities, and more. With a presence in over 170 countries and $200+ million invested in elite sponsorships, FxPro has earned over 120 industry awards for its innovative technology and reliable services. The launch of BankPro marks the Group’s expansion into digital private banking, combining its expertise in trading with cutting-edge financial solutions designed for the modern client. To know more please contact +1 242 603 2226. Media Contact Brand: BankPro Limited Contact: Media team Email: info@bankpro.com Website: https://www.bankpro.com The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...